



☆ **SESSION** PO.ET02.12 - Antibody-Based Cancer Therapeutics

➞ Add To My Itinerary

3

📅 April 29, 2025, 2:00 PM - 5:00 PM

📍 Section 15

DESCRIPTION

A link to the e-poster site will be made available at 12:00 PM CT on Friday, April 25, the first day of the Annual Meeting. E-posters will remain available to registered attendees through October 31, 2025.

☆ **5455 / 13 - TAVO605, a novel CD318 (CDCP1) ADC, for the treatment of solid cancers that are non-responding or resistant to Enhertu treatment**

Guangmao Mu, Fulai Zhou, Honglei Bi, Zhengxia Zha, Sheng Huang, Ying Jin, Mingcan Yu, Chao Han, Mark Chiu, Di Zhang.

Tavotek Biotherapeutics, Suzhou, China,
Tavotek Biotherapeutics, Lower Gwynedd, PA



☆ **SESSION** **PO.ET02.11 - Antibody-Based Cancer Therapeutics**

➡ Add To My Itinerary

2

📅 April 28, 2025, 2:00 PM - 5:00 PM

📍 Section 15

DESCRIPTION

A link to the e-poster site will be made available at 12:00 PM CT on Friday, April 25, the first day of the Annual Meeting. E-posters will remain available to registered attendees through October 31, 2025.


☆ **2863 / 2 - TAVO307, a novel ADC targeting CDH17, for the therapy of gastrointestinal cancers**
Guangmao Mu, Fulai Zhou, Zhengxia Zha, Sheng Huang, Ying Jin, Yuanting Chen, Mark Chiu, Di Zhang. Tavotek Biotherapeutics, Suzhou, China, Tavotek Biotherapeutics, Lower Gwynedd, PA


☆ **2880 / 19 - TM4SF1 as a novel target for different modalities (mAb, bispecific ADC, targeted siRNA) for the treatment of different solid tumor cancers**
Mingquan Xie, Peter Li, Han Lu, ShuTing Dong, Nicole Wilski, Poonam Pandey, Nishida Motohiko, Peter Haytko, Mark Chiu, Maria P. MacWilliams. Tavotek Lab Inc., Suzhou, China, Tavotek Lab Inc., Lower Gwynedd, PA



SESSION PO.IM01.05 - T Cell Engagers

 Add To My Itinerary

 April 28, 2025, 2:00 PM - 5:00 PM

 Section 38

DESCRIPTION

A link to the e-poster site will be made available at 12:00 PM CT on Friday, April 25, the first day of the Annual Meeting. E-posters will remain available to registered attendees through October 31, 2025.

☆ **3517 / 25 - A bispecific pan- $\gamma\delta$ T cell engager with IL-15 fusion that activates both $\delta 1$ and $\delta 2$ types of $\gamma\delta$ T cells for the treatment of acute myeloid leukemia**

Mingcan Yu, Peng Chen, Ying Jin, Fulai Zhou, Honglei Bi, Mark Chiu, Di Zhang. Tavotek Biotherapeutics, Lower Gwynedd, PA, Tavotek Biotherapeutics, Suzhou, China



SESSION

PO.CTP01.02 - Phase I Clinical Trials in Progress 2

Add To My Itinerary

April 29, 2025, 9:00 AM - 12:00 PM

Section 50

DESCRIPTION

A link to the e-poster site will be made available at 12:00 PM CT on Friday, April 25, the first day of the Annual Meeting. E-posters will remain available to registered attendees through October 31, 2025.

☆ **CT185 / 2 - Trispecific EGFR x cMET x VEGF antibody, TAVO412, has clinical responses in esophageal and lung cancers**

Mark Chiu¹, Wei Zhang², Yanjiao Yu², Helen Jiang², Chao Han¹

¹Tavotek Lab Inc., Lower Gwynedd, PA,
²Tavotek Lab Inc., Suzhou, China